Perspective for prophylaxis and treatment of cervical cancer: an immunological approach
- PMID: 22251005
- PMCID: PMC4164215
- DOI: 10.3109/08830185.2011.637254
Perspective for prophylaxis and treatment of cervical cancer: an immunological approach
Abstract
As the second most common cause of cancer-related death in women, human papilloma virus (HPV) vaccines have been a major step in decreasing the morbidity and mortality associated with cervical cancer. An estimated 490,000 women are diagnosed with cervical cancer each year. Increasing knowledge of the HPV role in the etiology of cervical cancer has led to the development and introduction of HPV-based vaccines for active immunotherapy of cervical cancer. Immunotherapies directed at preventing HPV-persistent infections. These vaccines are already accessible for prophylaxis and in the near future, they will be available for the treatment of preexisting HPV-related neoplastic lesions.
Copyright © Informa Healthcare USA, Inc.
Conflict of interest statement
Similar articles
-
[Cytology and DNA HPV-testing in the era of HPV-vaccine].Ginekol Pol. 2007 Sep;78(9):696-700. Ginekol Pol. 2007. PMID: 18159823 Polish.
-
Quadrivalent Human Papillomavirus Vaccine: Recommendations of the Advisory Committee on Immunization Practices (ACIP).MMWR Recomm Rep. 2007 Mar 23;56(RR-2):1-24. MMWR Recomm Rep. 2007. PMID: 17380109
-
HPV vaccines and cervical cancer.Ann Oncol. 2008 Jul;19 Suppl 5:v48-51. doi: 10.1093/annonc/mdn310. Ann Oncol. 2008. PMID: 18611900 No abstract available.
-
Human papillomavirus vaccine: the beginning of the end for cervical cancer.Isr Med Assoc J. 2007 Mar;9(3):156-8. Isr Med Assoc J. 2007. PMID: 17402325 Review.
-
Review of current knowledge on HPV vaccination: an appendix to the European Guidelines for Quality Assurance in Cervical Cancer Screening.J Clin Virol. 2007 Mar;38(3):189-97. doi: 10.1016/j.jcv.2006.12.009. Epub 2007 Jan 25. J Clin Virol. 2007. PMID: 17258503 Review.
Cited by
-
Is the Anal Component of the Anogenital HPV-Related Disease Overlooked During the Surveillance of Patients Treated for Cervical Intraepithelial Neoplasia?Cureus. 2023 Sep 5;15(9):e44731. doi: 10.7759/cureus.44731. eCollection 2023 Sep. Cureus. 2023. PMID: 37674762 Free PMC article.
-
Immunological characterization of a modified vaccinia virus Ankara vector expressing the human papillomavirus 16 E1 protein.Clin Vaccine Immunol. 2014 Feb;21(2):147-55. doi: 10.1128/CVI.00678-13. Epub 2013 Dec 4. Clin Vaccine Immunol. 2014. PMID: 24307238 Free PMC article.
-
Koch's postulates and the pathogenesis of comparative infectious disease causation associated with Bartonella species.J Comp Pathol. 2013 Feb;148(2-3):115-25. doi: 10.1016/j.jcpa.2012.12.003. Epub 2013 Feb 27. J Comp Pathol. 2013. PMID: 23453733 Free PMC article.
References
-
- Brinkman JA, Caffrey AS, Muderspach LI, et al. The impact of anti HPV vaccination on cervical cancer incidence and HPV induced cervical lesions: consequences for clinical management. Eur J Gynaecol Oncol. 2005;26:129–142. - PubMed
-
- Kahn JA. HPV vaccination for the prevention of cervical intraepithelial neoplasia. N Engl J Med. 2009;361:271–278. - PubMed
-
- Gershenson DM. Gynecologic Cancer: Controversies in Management. Philadelphia, PA: Elserver; 2004.
-
- Hoskins WJ. Principles and Practive of Gynecologic Oncology. 4. Philadelphia, PA: Lippincott Williams & Wilkins; 2005.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Research Materials